Arcadia Biosciences, Inc. (RKDA): Entry into a Material Definitive Agreement

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 rkda-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 11, 2026 between Arcadia Biosciences, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on

Event · Offering · proposed
Instrument
common stock (or pre-funded warrants in lieu thereof)
Gross proceeds
approximately $4 million
Shares
3,883,496 shares
Price per share
$1.03 per share
Use of proceeds
working capital and general corporate purposes

Facts are quoted from the filing text and checked against it.

Original reporting
Published Jun 15, 2026, 3:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 3:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$RKDA
Neutral
medium confidence
Mentioned
$RKDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RKDANeutralMed
01

Why it matters

A newly disclosed private placement agreement can change expectations for share count, cash runway, and future financing needs; it may also affect volatility around closing and resale registration plans referenced in the agreement.

02

Market read

This is a primary-source disclosure of a new financing agreement, relevant for dilution and near-term risk pricing in RKDA.

03

What to watch

Traders will need the missing agreement details (subscription amount, share/warrant counts, conversion/exercise terms, closing conditions) to assess dilution and overhang accurately.

Relevance 6/10Novelty 8/10Timing: Filed June 15, 2026 (8-K)

Background

The article is an SEC EDGAR 8-K (Item 1.01 and Item 3.02) attaching a securities purchase agreement dated June 11, 2026.

Company-level read

Ticker impact

$RKDANeutralMedium confidence
Context

Arcadia Biosciences filed an 8-K disclosing entry into a securities purchase agreement for an unregistered equity issuance (Item 1.01/3.02).

Expected impact

Likely modest negative-to-neutral bias from dilution overhang, with volatility around deal terms and closing mechanics.

Evidence & confidence

The text confirms a material definitive agreement and unregistered sales, but the excerpt does not include the specific size/price/terms needed to gauge dilution magnitude.

Market effects

Financing activity in biotech can influence read-through expectations for small-cap funding conditions and risk appetite.

No clear regional linkage beyond US small-cap biotech capital markets.

Limited; this is company-specific private placement disclosure.

Counterpoint

If the placement terms are structured to minimize dilution (e.g., favorable pricing, warrants limited), the market may re-rate the financing as supportive rather than dilutive.

Key entities

  • Arcadia Biosciences, Inc.

    Company entering a material definitive securities purchase agreement and conducting unregistered equity sales under Section 4(a)(2)/Rule 506.

  • Continental Stock Transfer & Trust Company

    Escrow agent for subscription amounts deposited to fund the transaction.

  • Placement Agent (unnamed in excerpt)

    Referenced in timing/disclosure mechanics and escrow agreement context.

Related articles

$RKDAMed

Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights -- Zola ® Q3 revenues increase 24% year-over-year, largest quarterly sales ever -- -- New 1L espresso formulation ships this month, slim cans to launch in early 2027 --

$RKDAMed

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights – Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 m

$RKDAMedAI 9/10

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Arcadia Biosciences (Nasdaq: RKDA) said it closed a $4 million private placement under Nasdaq rules, selling 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options to buy up to 3,883,496 shares each at $1.03/share. Gross proceeds were about $4 million. H.C. Wainwright & Co. was placement agent; proceeds will fund working capital and general corporate purposes.

$ANTHighAI 9/10

Key facts: Anthropic Reports $33.2B Revenue, Raises $10B; Cash Could Exceed $230B

Anthropic (ANT) reported $33.2B revenue for nine months, up 12x YoY, with an $81B annualized run rate but a $1.3B operating loss. It raised $10B from Alphabet and completed a $26B private placement. Analysts estimate cash could exceed $230B post-IPO. Risks include capital commitments and data-center plans. Analysts' ratings vary: Outperform, Neutral, and a $92 fair value estimate.

$ZBRAHigh

Zebra Technologies Sees 2027 Growth as Delivery Refreshes Offset Memory Cost Pressures

Zebra Technologies (ZBRA) raised prices to offset higher costs, with no broad customer project deferrals. AI applications and productivity improvements are expected to drive growth. The company anticipates $1B in free cash flow this year, with $400M remaining under its repurchase authorization. Investor sentiment has improved due to secured memory supply and interest in AI and automation.